TuHURA Biosciences Receives U.S. Patent For Administration Of DOR Antagonists

TuHURA Biosciences, Inc. (NASDAQ: HURA) has been granted U.S. Patent No. 12,734,168 for its novel therapeutic approach involving Delta Opioid Receptor (DOR) antagonists aimed at enhancing cancer immunotherapy. The patent covers the administration of DOR antagonists to patients with cancers associated with DOR-expressing Myeloid Derived Suppressor Cells (MDSCs) and includes various combination therapies for treating and preventing cancer and metastasis.